IRCT138805222340N1已完成2 期
Evaluating the Effect of Pioglitazone on proteinuria in patients with non diabetic renal disease
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 80 years（—）
- 性别
- All
入选标准
- •1. proteinuria (>500 mg/ day) for at least 6 months; 2. controlled blood pressure for at least 6 months; 3. age more than 18 years; 4. BMI less than 30; 5. serum creatinin less than 6 mg/dl; 6. no diabetes; 7. not using immunosuppressor agents; 8. no heart failure; 9. no liver disease. Exclusion criteria: 1. changes in doses of drugs which have effect on proteinuria (for example ACEI); 2. incidense of complications attributable to the drugs.
排除标准
- 未提供
研究者
相似试验
已完成
3 期
Effect of a lowering blood glucose drug on protein loss with urine in patient with kidney disease due to diabetDiabetic nephropathy.Diabetes mellitus With renal complicationsE10-E14 :IRCT2013102115105N1Vice chancellor for research, Tabriz University of Medical Sciences60
尚未招募
2 期
Pioglitazone and non-alcoholic fatty liveron-alcoholic fatty liver.Fatty (change of) liver, not elsewhere classifiedK76.0IRCT20210614051574N3Esfahan University of Medical Sciences44
进行中（未招募）
1 期
Influence of the PPAR gamma -agonist Pioglitazone on endothelial function in the peripheral and myocardial vascular territories and on myocardial efficiency in obese subjects - PioglitazoneThere is an association between insulin resistance and endothelial dysfunction which is thought to be a critical factor in the development of vascular disease and thus an important factor in the development of atherosclerosis, hypertension and heart failure. Endothelial dysfunction can occur even in the vascular absence of angiographically defined disease and can be detected early in the spectrum of insulin resistance.EUCTR2004-003861-34-ATDepartment of Nuclear Medicine62
进行中（未招募）
不适用
Effect of pioglitazone in patienst with Adrenomyeloneuropathy.X-linked adrenoleukodystrophyEUCTR2011-006113-34-ESAURORA PUJOL ONOFRE
已完成
不适用
A study to investigate the effect of pioglitazone on whole body and myocardial glucose uptake and myocardial blood flow/coronary vasodilator reserve in patients with familial combined hyperlipidaemiaISRCTN78563659Takeda Europe R and D Centre (UK)26